Skip to main content
Shasta County's Response to Local Emergencies

Google Translate service may not work with Internet Explorer.

Medicine to treat & prevent COVID-19

Healthcare providers: Please visit our Medical Professionals page

Most people with COVID-19 have mild illness and can recover at home. Even so, there are some things you should do: your doctor, monitoring your symptoms, and knowing when you need emergency medical care.

There are now medicines available to treat people with mild-to-moderate COVID-19 who are at risk for developing severe COVID-19. Talk to your doctor if you feel that you may be at higher risk. The medicines must be prescribed by a healthcare provider. Some can be taken by mouth and can be given outside the hospital. Others are given by injection or IV.

When logistical or supply constraints limit the availability of medicine to treat and prevent COVID-19, individuals at the highest risk may be prioritized until more product become available.

Prioritization is based on 4 key elements: age, vaccination status, immune status, and clinical risk factors.

For more details on priority health conditions, see the NIH Statement on Patient Prioritization for Outpatient Therapies | COVID-19 Treatment Guidelines (nih.gov) 

To learn more, see the information below and talk to your doctor.

*NEW* - Test to treat 

Get tested for COVID-19, receive a prescription for treatment from a health care provider (if appropriate for the patient) and have the prescription filled.

How to Make an Appointment: Schedule online

Hours of operation: 9 AM-5 PM Monday-Friday

Address: 2420 Breslauer Way, Redding 96001

Oral Medicines to Treat Mild to Moderate COVID-19

Paxlovid and Molnupiravir are antiviral medicines taken by mouth. The Food and Drug Administration (FDA) has issued emergency use authorizations (EUAs*) for these medicines. They can be used to treat people with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death. Treatment is given as soon as possible and must begin within 5 days of the start of symptoms. Supplies are limited; those at the highest risk may be prioritized until supply improves. 

  • Paxlovid is for people ages 12 and over weighing at least 88 pounds.
  • Molnupiravir is for adults age 18 or over. It is not recommended for use during pregnancy.

 For more information, see the fact sheet for patients/caregivers for Paxlovid and Molnupiravir.

Where to Get Paxlovid and Molnupiravir 

These medicines are only available by prescription and are currently in limited supply.


Ask your provider if you are eligible for treatment. If they give you a prescription to fill at a pharmacy, call ahead to make sure the medicine is available.

If you need to leave home to get medical care, wear a non-cloth mask with multiple layers of non-woven material and a nose wire. This will help to protect others. Go to Stop the Spread for more information.

 

You may use this website to find where a medication is available near you https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com or use the Pharmacies located below.

Pharmacy Address Therapeutic

Phone number

Shasta Community Health Center 21035 Placer St, Redding, CA 96001 Paxlovid & Lagevrio (molnupiravir) (530) 246-5710
CVS Store 1035 Placer Street, Suite 110, Redding, CA 96001 Paxlovid & Lagevrio (molnupiravir) (530) 999-6073
CVS Store 2025 Court Street, Suite A, Redding, CA 96001 Lagevrio (molnupiravir) (530) 999-6072
Shasta Regional Medical Center 1450 Liberty St, Redding, CA 96001 Paxlovid Inventory Reporting Status: Unknown. Inventory has not been reported in the last 2 weeks. Please contact provider to make sure product is available. (530) 244-5401
Redding Rancheria 1441 Liberty Street, Redding, CA 96001 Paxlovid Inventory Reporting Status: Unknown. Inventory has not been reported in the last 2 weeks. Please contact provider to make sure product is available. (530) 224-2700
Rite Aid 1801 Eureka Way, Redding, CA 96001 Lagevrio (molnupiravir) (530) 243-5500
CVS Store 3375 Placer St, Redding, CA 96001 Lagevrio (molnupiravir) (530) 241-7328
CVS Store 317 Lake Boulevard, Suite B, Redding, CA 96003 Lagevrio (molnupiravir) (530) 999-6099
Walgreens Store 115 Lake Blvd E, Redding, CA 96003 Paxlovid & Lagevrio (molnupiravir) (530) 229-1519
Rite Aid 975 East Cypress Avenue, Redding, CA 96002 Paxlovid & Lagevrio (molnupiravir) (530) 223-3995
CVS Store 1060 E Cypress Ave, Redding, CA 96002 Paxlovid & Lagevrio (molnupiravir) (530) 221-5575
CVS Store 1280 Dana Dr, Redding, CA 96003 Lagevrio (molnupiravir) (530) 224-1437
Omnicare of Redding 5200 Churn Creek Rd. Suite A, Redding, CA 96002 Paxlovid & Lagevrio (molnupiravir) (530) 224-3373
Rite Aid 6424 Westside Road, Redding, CA 96001 Paxlovid & Lagevrio (molnupiravir) (530) 243-3616

Pharmacy Address  Therapeutic 

Phone number

Rite Aid 3095 Mcmurray Drive, Anderson, CA 96007 Lagevrio (molnupiravir) & Paxlovid (530) 365-5753
CVS Store 2975 East Street, Anderson, CA 96007 Lagevrio (molnupiravir) (530) 744-6024
Anderson Family Health Center 2965 East Street, Anderson, CA 96007 Lagevrio (molnupiravir) & Paxlovid (530) 378-0486
AndersonRX Pharmacy 2940 East St., Anderson, CA 96007 Lagevrio (molnupiravir) & Paxlovid (530) 378-5566
Safeway Pharmacy 2601 Balls Ferry Road, Anderson, CA 96007 Lagevrio (molnupiravir) & Paxlovid (530) 365-1010

Pharmacy Address Therapeutic

Phone number

Rite Aid 5350 Shasta Dam Boulevard, Shasta Lake, CA 96019-9402 Paxlovid & Lagevrio (molnupiravir) (530) 275-1532

Pharmacy Address Therapeutic Phone number
Rite Aid 9340 Deschutes Rd, Palo Cedro, CA 96073 Paxlovid & Lagevrio (molnupiravir) (530) 547-4403

Pharmacy Address Therapeutic

Telephone

Safeway Pharmacy 37264 Main Street, Burney, CA 96013 Lagevrio (molnupiravir) (530) 335-4101
Rite Aid 37435 Main Street, Burney, CA 96013-4372 Paxlovid & Lagevrio (molnupiravir) (530) 335-4860

Pharmacy Address Therapeutic

Phone number

Mayers Memorial Hospital District 343563 Highway 299 East, Fall River Mills, CA 96028 Paxlovid & Lagevrio (molnupiravir) (530) 336-7558

Monoclonal Antibody Medicines to Treat Mild to Moderate COVID-19

Monoclonal antibody products received EUA for the treatment of mild to moderate COVID-19 in patients not hospitalized who are at high risk for progressing to severe disease and/or hospitalization. The medicines listed below are treatments for COVID-19 given by injection. Treatment should be given as soon as possible and must begin within 10 days of the start of symptoms.

  • Bebtelovimab: Is a monoclonal antibody-based medicine. It is given through a vein. The FDA has issued an EUA* for Betelovimab for use in people ages 12 and over who weigh at least 88lbs. This treatment is thought to be effective against the Omicron variant. For more information, see Fact sheet for patient/caregivers. Supplies are limited, those at highest risk may be prioritized until more product becomes available.
  • Sotrovimab is a monoclonal antibody-based medicine. Sotrovimab is no longer authorized by the FDA for use in California due to increases of the Omicron sub-variant BA.2. See CDPH update 3-30-22 for details. It is given through a vein over 30 minutes. The FDA has issued an EUA* for Sotrovimab for use in people ages 12 and over who weigh at least 88 pounds. For more information, see Fact sheet for patient/caregivers. Supplies are currently unavailable.
  • Bamlanivimab and Etesevimab (Bam/Ete) is a monoclonal antibody-based medicine. Bamlanivimab and Etesevimab (Bam/Ete) are no longer authorized by the FDA for use in California due to increases of the Omicron sub-variant BA.1. It is given by through a vein during a single visit. The FDA has issued an EUA* for Bam/Ete for treatment of mild-to-moderate disease and also for post-exposure prophylaxis (see below). It can be given to people of any age including infants. For more information, see Fact sheet for patient/caregivers. Supplies are currently unavailable.
  • Casirivimab and Imdevimab (REGEN-COV) is a monoclonal antibody-based medicine. Casirivimab and Imdevimab (REGEN-COV) are no longer authorized by the FDA for use in California due to increases of the Omicron sub-variant BA.1 It is given during a single visit through a vein or by several injections just under the skin. The FDA has issued an EUA* for REGEN-COV for treatment of mild-to-moderate disease and also for post-exposure prophylaxis (see below). It can be given to people ages 12 and over who weigh at least 88 pounds. For more information, see Fact sheet for patient/caregivers. Supplies are currently unavailable.  

Facilities offering these medicines are limited and supply is scarce.

These medicines are only available by prescription. Ask your provider if you are eligible for treatment. Treatment may be available at one of the locations listed below.


PRIMARY SITES
 DELIVERING MONOCLONAL ANTIBODIES FOR COVID-19 TREATMENT

  • Dr. Paul Davis: Private pay (submit to insurance for reimbursement), community access, based on availability: (530) 768-9490; Visit www.antibodyclinic.org to determine eligibility, daytime, and after-hours services, weekends, home visits

EMERGENCY DEPARTMENTS DELIVERING MONOCLONAL ANTIBODIES FOR COVID-19 TREATMENT (not recommended for non-emergencies)

  • Mercy Medical Center Redding
  • Shasta Regional Medical Center
  • Mayers Memorial Hospital

If you need to leave home to get medical care, wear a non-cloth mask with multiple layers of non-woven material and a nose wire. This will help to protect others. Go to Stop the Spread for more information.


Medicines to Prevent COVID-19

Pre-exposure prophylaxis (medicines used to prevent COVID-19 infection in the future)

Evusheld is a monoclonal antibody-based medicine. It is used before a person is exposed to COVID-19 to prevent them from getting COVID-19. It is used in people who either can’t get a COVID-19 vaccine for medical reasons or who may not respond well to a vaccine because they have a weak immune system due to a medical condition or treatment. It is given as 2 separate injections into the buttocks during a single visit. More doses may need to be given every 6 months. The FDA has issued an EUA* for Evusheld. It is for people ages 12 and over who weigh at least 88 pounds.

For more information, talk to your doctor and see the Fact sheets for patient/caregivers for Evusheld. Supplies are limited.

Evusheld is only available by prescription and referral ONLY.

Ask your provider if you are eligible for treatment. Treatment may be available by referral from your provider to receive treatment at select regional locations.


Post-exposure prophylaxis (medicine used to prevent infection after being exposed to someone with COVID-19)

Bamlanivimab and Etesevimab (Bam/Ete) and Casirivimab and Imdevimab (REGEN-COV) are monoclonal antibody treatments. These treatments are not effective against the Omicron variant and are not currently authorized for use. They are used after a person has been exposed to COVID-19 to prevent them from becoming infected. They are given to people who are unvaccinated or who may not respond well to a vaccine because they have a weak immune system due to a medical condition or treatment.

  • Bam/Ete is for people of any age, including infants. It is given by an infusion into a vein during a single visit.
  • REGEN-COV is for people ages 12 and over who weigh at least 88 pounds. It is given during a single visit by an infusion into a vein or by several injections under the skin.

For more information, talk to your doctor and see the fact sheets for patients/caregivers for Bam/Ete, and REGEN-COV.

Other Medicines to Treat Mild to Moderate COVID-19

  • Remdesivir (Vekury) is an antiviral medication. It is approved by the FDA for treating patients in hospitals but is also used for outpatient treatment. For outpatient treatment, it is given through a vein for 3 days in a row. This treatment is thought to be effective against the Omicron variant. For more information, see Fact sheet for patient/caregivers.

Health care professionals may also prescribe other commonly used medications to treat COVID-19 complications (e.g., steroids). For more information see the Drug and Treatment Tracker for the history and current recommendations for the most talked-about drugs and treatments for COVID-19. 

Emergency Use Authorization

In an emergency when lives are at risk, the FDA can issue a EUA to make a treatment available before it has completed a formal approval process as long as there’s evidence that strongly suggests that people benefit from the treatment. The FDA can also issue a EUA for unapproved uses of approved drugs for life-threatening conditions. Certain conditions must be met for a EUA to be issued, including that there are no other adequate, approved, and available options.

To learn more about EUAs, visit the FDA EUA webpage